{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:25:28Z","timestamp":1792783528167,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T00:00:00Z","timestamp":1588204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T00:00:00Z","timestamp":1588204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GW Research Ltd, Cambridge, UK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s40263-020-00726-4","type":"journal-article","created":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T00:06:08Z","timestamp":1588205168000},"page":"661-672","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug\u2013Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5864-9185","authenticated-orcid":false,"given":"Elinor","family":"Ben-Menachem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boudewijn","family":"Gunning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen Mar\u00eda","family":"Arenas Cabrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevan","family":"VanLandingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Crockett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Critchley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Wray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bola","family":"Tayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilmour","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Toledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,30]]},"reference":[{"key":"726_CR1","unstructured":"Epidiolex\u00ae (cannabidiol) oral solution, CV [prescribing information]. Carlsbad, CA: Greenwich Biosciences, Inc. 2018."},{"key":"726_CR2","unstructured":"GW Pharmaceuticals, plc. Epidyolex 100 mg\/ml oral solution: summary of product characteristics (SmPC). 2019."},{"key":"726_CR3","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","volume":"376","author":"O Devinsky","year":"2017","unstructured":"Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376:2011\u201320.","journal-title":"N Engl J Med."},{"key":"726_CR4","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","volume":"378","author":"O Devinsky","year":"2018","unstructured":"Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med. 2018;378:1888\u201397.","journal-title":"N Engl J Med."},{"key":"726_CR5","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","volume":"391","author":"EA Thiele","year":"2018","unstructured":"Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled Phase 3 trial. Lancet. 2018;391:1085\u201396.","journal-title":"Lancet."},{"key":"726_CR6","doi-asserted-by":"publisher","unstructured":"Miller I, Scheffer IE, Gunning B, Sanchez-Carpintero R, Gil-Nagel A, Perry MS, et al. Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in Dravet syndrome: a randomized clinical trial. JAMA Neurol. 2020;https:\/\/doi.org\/10.1001\/jamaneurol.2020.007, [Epub ahead of print].","DOI":"10.1001\/jamaneurol.2020.007"},{"key":"726_CR7","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/epi.14628","volume":"60","author":"O Devinsky","year":"2019","unstructured":"Devinsky O, Nabbout R, Miller I, Laux L, Zolnowska M, Wright S, et al. Long-term cannabidiol treatment in patients with Dravet syndrome: an open-label extension trial. Epilepsia. 2019;60:294\u2013302.","journal-title":"Epilepsia."},{"key":"726_CR8","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/epi.14670","volume":"60","author":"E Thiele","year":"2019","unstructured":"Thiele E, Marsh E, Mazurkiewicz-Beldzinska M, Halford JJ, Gunning B, Devinsky O, et al. Cannabidiol in patients with Lennox-Gastaut syndrome: interim analysis of an open-label extension study. Epilepsia. 2019;60:419\u201328.","journal-title":"Epilepsia."},{"key":"726_CR9","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1111\/epi.14477","volume":"59","author":"JP Szaflarski","year":"2018","unstructured":"Szaflarski JP, Bebin EM, Comi AM, Patel AD, Joshi C, Checketts D, et al. Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: expanded access program results. Epilepsia. 2018;59:1540\u20138.","journal-title":"Epilepsia."},{"key":"726_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1528-1167.2011.03177.x","volume":"52","author":"PR Camfield","year":"2011","unstructured":"Camfield PR. Definition and natural history of Lennox-Gastaut syndrome. Epilepsia. 2011;52:3\u20139.","journal-title":"Epilepsia."},{"key":"726_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1528-1167.2011.02994.x","volume":"52","author":"C Dravet","year":"2011","unstructured":"Dravet C. The core Dravet syndrome phenotype. Epilepsia. 2011;52:3\u20139.","journal-title":"Epilepsia."},{"key":"726_CR12","first-page":"107","volume":"13","author":"PK Crumrine","year":"2011","unstructured":"Crumrine PK. Management of seizures in Lennox-Gastaut syndrome: Paediatr Drugs. 2011;13:107\u201318.","journal-title":"Management of seizures in Lennox-Gastaut syndrome: Paediatr Drugs."},{"key":"726_CR13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/epi.12567","volume":"55","author":"BFD Bourgeois","year":"2014","unstructured":"Bourgeois BFD, Douglass LM, Sankar R. Lennox-Gastaut syndrome: a consensus approach to differential diagnosis. Epilepsia. 2014;55:4\u20139.","journal-title":"Epilepsia."},{"key":"726_CR14","doi-asserted-by":"publisher","first-page":"505","DOI":"10.3389\/fneur.2017.00505","volume":"8","author":"JH Cross","year":"2017","unstructured":"Cross JH, Auvin S, Falip M, Striano P, Arzimanoglou A. Expert opinion on the management of Lennox-Gastaut syndrome: treatment algorithms and practical considerations. Front Neurol. 2017;8:505.","journal-title":"Front Neurol."},{"key":"726_CR15","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11940-018-0537-y","volume":"20","author":"J Ziobro","year":"2018","unstructured":"Ziobro J, Eschbach K, Sullivan JE, Knupp KG. Current treatment strategies and future treatment options for Dravet syndrome. Curr Treat Options Neurol. 2018;20:52.","journal-title":"Curr Treat Options Neurol."},{"issue":"18\u201334","key":"726_CR16","first-page":"e3","volume":"68","author":"EC Wirrell","year":"2017","unstructured":"Wirrell EC, Laux L, Donner E, Jette N, Knupp K, Meskis MA, et al. Optimizing the diagnosis and management of Dravet Syndrome: recommendations from a North American consensus panel. Pediatr Neurol. 2017;68(18\u201334):e3.","journal-title":"Pediatr Neurol."},{"key":"726_CR17","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1002\/cpdd.665","volume":"8","author":"G Morrison","year":"2019","unstructured":"Morrison G, Crockett J, Blakey G, Sommerville K. A Phase 1, open-label, pharmacokinetic trial to investigate possible drug-drug interactions between clobazam, stiripentol, or valproate and cannabidiol in healthy subjects. Clin Pharmacol Drug Dev. 2019;8:1009\u201331.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"726_CR18","first-page":"5","volume":"61","author":"P Patsalos","year":"2019","unstructured":"Patsalos P, Gidal B, Szaflarski J, VanLandingham K, Critchley D, Morrison G. Drug-drug interaction (DDI) studies with coadministration of cannabidiol (CBD) and clobazam (CLB), valproate (VPA), stiripentol (STP) or midazolam (MDZ) in healthy volunteers (HVTS) and adults with epilepsy. Dev Med Child Neurol. 2019;61:5\u201314.","journal-title":"Dev Med Child Neurol."},{"key":"726_CR19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.pharmthera.2004.10.013","volume":"106","author":"TKL Kiang","year":"2005","unstructured":"Kiang TKL, Ensom MHH, Chang TKH. UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther. 2005;106:97\u2013132.","journal-title":"Pharmacol Ther."},{"key":"726_CR20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2174\/1389450118666170125144557","volume":"19","author":"P Manikandan","year":"2018","unstructured":"Manikandan P, Nagini S. Cytochrome P450 structure, function and clinical significance: a review. Curr Drug Targets. 2018;19:38\u201354.","journal-title":"Curr Drug Targets."},{"key":"726_CR21","first-page":"391","volume":"76","author":"T Lynch","year":"2007","unstructured":"Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007;76:391\u20136.","journal-title":"Am Fam Physician."},{"key":"726_CR22","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.lfs.2011.05.018","volume":"89","author":"R Jiang","year":"2011","unstructured":"Jiang R, Yamaori S, Takeda S, Yamamoto I, Watanabe K. Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sci. 2011;89:165\u201370.","journal-title":"Life Sci."},{"key":"726_CR23","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/FPC.0b013e32835ea0b2","volume":"23","author":"Y Ghodke-Puranik","year":"2013","unstructured":"Ghodke-Puranik Y, Thorn CF, Lamba JK, Leeder JS, Song W, Birnbaum AK, et al. Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2013;23:236\u201341.","journal-title":"Pharmacogenet Genomics."},{"key":"726_CR24","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1089\/can.2015.0012","volume":"1","author":"I Ujv\u00e1ry","year":"2016","unstructured":"Ujv\u00e1ry I, Hanu\u0161 L. Human metabolites of cannabidiol: a review on their formation, biological activity, and relevance in therapy. Cannabis Cannabinoid Res. 2016;1:90\u2013101.","journal-title":"Cannabis Cannabinoid Res."},{"key":"726_CR25","unstructured":"Biocodex. Diacomit 250 mg hard capsules: summary of product characteristics (SmPC). 2018."},{"key":"726_CR26","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.lfs.2011.02.017","volume":"88","author":"S Yamaori","year":"2011","unstructured":"Yamaori S, Ebisawa J, Okushima Y, Yamamoto I, Watanabe K. Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety. Life Sci. 2011;88:730\u20136.","journal-title":"Life Sci."},{"key":"726_CR27","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1124\/dmd.111.041384","volume":"39","author":"S Yamaori","year":"2011","unstructured":"Yamaori S, Okamoto Y, Yamamoto I, Watanabe K. Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos. 2011;39:2049\u201356.","journal-title":"Drug Metab Dispos."},{"key":"726_CR28","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2133\/dmpk.DMPK-12-RG-129","volume":"28","author":"R Jiang","year":"2013","unstructured":"Jiang R, Yamaori S, Okamoto Y, Yamamoto I, Watanabe K. Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19. Drug Metab Pharmacokinet. 2013;28:332\u20138.","journal-title":"Drug Metab Pharmacokinet."},{"key":"726_CR29","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1124\/dmd.112.047878","volume":"41","author":"A Al Saabi","year":"2013","unstructured":"Al Saabi A, Allorge D, Sauvage F-L, Tournel G, Gaulier J-M, Marquet P, et al. Involvement of UDP-glucuronosyltransferases UGT1A9 and UGT2B7 in ethanol glucuronidation, and interactions with common drugs of abuse. Drug Metab Dispos. 2013;41:568\u201374.","journal-title":"Drug Metab Dispos."},{"key":"726_CR30","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1124\/dmd.32.11.1279","volume":"32","author":"C Giraud","year":"2004","unstructured":"Giraud C, Tran A, Rey E, Vincent J, Tr\u00e9luyer J-M, Pons G. In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos. 2004;32:1279\u201386.","journal-title":"Drug Metab Dispos."},{"key":"726_CR31","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/epi.13060","volume":"56","author":"AL Geffrey","year":"2015","unstructured":"Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56:1246\u201351.","journal-title":"Epilepsia."},{"key":"726_CR32","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s40263-019-00624-4","volume":"33","author":"JW Wheless","year":"2019","unstructured":"Wheless JW, Dlugos D, Miller I, Oh DA, Parikh N, Phillips S, et al. Pharmacokinetics and tolerability of multiple doses of pharmaceutical-grade synthetic cannabidiol in pediatric patients with treatment-resistant epilepsy. CNS Drugs. 2019;33:593\u2013604.","journal-title":"CNS Drugs."},{"key":"726_CR33","unstructured":"Morrison G, Taylor L, Crockett J, Critchley D, Tayo B. A phase 1 investigation into the potential effects of cannabidiol on CYP3A4-mediated drug-drug interactions in healthy volunteers. In: AES 2018 Annual Meeting Abstract Database. AESnet.org. 2018."},{"key":"726_CR34","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1126\/science.3101178","volume":"235","author":"AE Rettie","year":"1987","unstructured":"Rettie AE, Rettenmeier AW, Howald WN, Baillie TA. Cytochrome P-450 \u2013 catalyzed formation of delta 4-VPA, a toxic metabolite of valproic acid. Science. 1987;235:890\u20133.","journal-title":"Science."},{"key":"726_CR35","first-page":"698","volume":"283","author":"AJ Sadeque","year":"1997","unstructured":"Sadeque AJ, Fisher MB, Korzekwa KR, Gonzalez FJ, Rettie AE. Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid. J Pharmacol Exp Ther. 1997;283:698\u2013703.","journal-title":"J Pharmacol Exp Ther."},{"key":"726_CR36","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0920-1211(01)00306-0","volume":"47","author":"S Arroyo","year":"2001","unstructured":"Arroyo S, de la Morena A. Life-threatening adverse events of antiepileptic drugs. Epilepsy Res. 2001;47:155\u201374.","journal-title":"Epilepsy Res."},{"key":"726_CR37","doi-asserted-by":"crossref","unstructured":"Gaston TE, Bebin EM, Cutter GR, Liu Y, Szaflarski JP, UAB CBD Program. Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia. 2017;58:1586\u201392.","DOI":"10.1111\/epi.13852"},{"key":"726_CR38","doi-asserted-by":"publisher","first-page":"e1204","DOI":"10.1212\/WNL.0000000000005254","volume":"90","author":"O Devinsky","year":"2018","unstructured":"Devinsky O, Patel AD, Thiele EA, Wong MH, Appleton R, Harden CL, et al. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 2018;90:e1204\u201311.","journal-title":"Neurology."},{"key":"726_CR39","doi-asserted-by":"publisher","first-page":"3458","DOI":"10.1002\/jps.23559","volume":"102","author":"J Heuberger","year":"2013","unstructured":"Heuberger J, Schmidt S, Derendorf H. When is protein binding important? J Pharm Sci. 2013;102:3458\u201367.","journal-title":"J Pharm Sci."},{"key":"726_CR40","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/j.1365-2125.1984.tb02401.x","volume":"17","author":"E Perucca","year":"1984","unstructured":"Perucca E, Grimaldi R, Gatti G, Pirracchio S, Crema F, Frigo GM. Pharmacokinetics of valproic acid in the elderly. Br J Clin Pharmacol. 1984;17:665\u20139.","journal-title":"Br J Clin Pharmacol."},{"key":"726_CR41","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","volume":"168","author":"K Posner","year":"2011","unstructured":"Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168:1266\u201377.","journal-title":"Am J Psychiatry."},{"issue":"Suppl. 1","key":"726_CR42","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2165\/00003088-198400091-00007","volume":"9","author":"WF Bowers","year":"1984","unstructured":"Bowers WF, Fulton S, Thompson J. Ultrafiltration vs equilibrium dialysis for determination of free fraction. Clin Pharmacokinet. 1984;9(Suppl. 1):49\u201360.","journal-title":"Clin Pharmacokinet."},{"key":"726_CR43","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s40263-018-0578-5","volume":"32","author":"L Taylor","year":"2018","unstructured":"Taylor L, Gidal B, Blakey G, Tayo B, Morrison G. A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs. 2018;32:1053\u201367.","journal-title":"CNS Drugs."},{"key":"726_CR44","unstructured":"US Food & Drug Administration (FDA). Clinical drug interaction studies\u2014cytochrome p450 enzyme- and transporter-mediated drug interactions guidance for industry [Internet]. 2020. https:\/\/www.fda.gov\/media\/134581\/download. Accessed 26 Feb 2020."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-020-00726-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-020-00726-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-020-00726-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T20:23:51Z","timestamp":1619727831000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-020-00726-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,30]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["726"],"URL":"https:\/\/doi.org\/10.1007\/s40263-020-00726-4","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,30]]},"assertion":[{"value":"30 April 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The sponsor adheres to current requirements of the USA and the EU so will not make individual de-identified participant data available; however, the protocol and statistical analysis plan will be made available upon request to the corresponding author.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Open access funding provided by Greenwich Biosciences, Inc. This trial was sponsored by GW Research Ltd, Cambridge, UK.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Elinor Ben-Menachem has received consulting honoraria from GW Pharmaceuticals companies, UCB, Sandoz, Eisai, and Bial and has been a principal investigator for GW Research Ltd. Boudewijn Gunning has received consultancy fees from GW Pharmaceuticals companies, Zogenix, and Ovid\/Takeda; has been a principal investigator for GW Research Ltd, Zogenix, LivaNova, Marinus Pharmaceuticals, and UCB; and is a member of the International Speakers Bureau of LivaNova. Carmen Mar\u00eda Arenas Cabrera has received consultancy fees from UCB, Eisai, Bial, and Esteve and has been a principal investigator for GW Research Ltd. Kevan VanLandingham is employed by Greenwich Biosciences, Inc. and owns shares in GW Pharmaceuticals plc. Bola Tayo and Gilmour Morrison are employed by GW Research Ltd and own shares in GW Pharmaceuticals plc. David Critchley, Louise Wray, and Julie Crockett are employed by GW Research Ltd and have share options in GW Pharmaceuticals plc. Manuel Toledo has received consulting honoraria and lecture fees from GW Pharmaceuticals companies, UCB Pharma, Eisai, Bial, Esteve, and Sanofi and has been a principal investigator for GW Research Ltd.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The protocol and informed consent forms were approved by local independent ethics committees. All procedures performed in studies involving human participants were in accordance with the International Council for Harmonisation Good Clinical Practice Consolidated Guideline, the applicable local laws and regulatory requirements of the countries in which the trial was conducted, and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Written informed consent\/assent was obtained from all individual patients included in the trial (or their parent\/legal representative) before any trial-specific procedures were performed or any patient-related data were collected.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}